TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33909194

Group type: EXPERIMENTAL
Intervention: Monthly pharmaceutical care follow-up for 6 months
Number of subjects: 184
Study: 32838701

Group type: EXPERIMENTAL
Intervention: Integrated neonatal care kit (iNCK) delivered by Lady Health Workers (LHW)
Number of subjects: 5286

Group type: COMPARATOR
Intervention: Local standard of care (control)
Number of subjects: 5286
Study: 33947355

Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day (maximum 50 mg/day) for 10 days
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo for oral intake once daily for 10 days
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 500
Study: 34044977

Group type: EXPERIMENTAL
Intervention: High-volume evacuation (HVE)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination of HVE and intraoral suction device
Number of subjects: 93

Group type: COMPARATOR
Intervention: Intraoral suction device alone
Number of subjects: 93
Study: 35322001

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with bevacizumab
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bevacizumab combined with paclitaxel chemotherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with bevacizumab (dMMR patients)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with bevacizumab (PMMR patients)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bevacizumab combined with paclitaxel chemotherapy (dMMR patients)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bevacizumab combined with paclitaxel chemotherapy (PMMR patients)
Number of subjects: 93
Study: 33569738

Group type: EXPERIMENTAL
Intervention: BEC (binimetinib, encorafenib, and cetuximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EC (encorafenib and cetuximab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CI/CF (cetuximab with irinotecan or FOLFIRI)
Number of subjects: 0
Study: 32488754

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (100 mg daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35525238

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for quitting smoking and weight gain prevention
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) plus contingency management (CM)
Number of subjects: 41
Study: 34473031

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 100
Study: 33724168

Group type: EXPERIMENTAL
Intervention: Ovulatory follicles (upregulated miRNAs)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subordinate follicles (downregulated miRNAs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of miRNA expression
Number of subjects: 6
Study: 34284567

Group type: EXPERIMENTAL
Intervention: High-dose pulsed methylprednisolone
Number of subjects: 15
Study: 33028418

Group type: COMPARATOR
Intervention: MCT with RT
Number of subjects: 80

Group type: COMPARATOR
Intervention: HIIT with RT
Number of subjects: 80
Study: 35218627

Group type: EXPERIMENTAL
Intervention: Core stability training combined with fire needle acupuncture
Number of subjects: 75

Group type: COMPARATOR
Intervention: Core stability training (Control group)
Number of subjects: 75
Study: 33170757

Group type: EXPERIMENTAL
Intervention: Story Friends vocabulary intervention program with explicit vocabulary instruction embedded in prerecorded storybooks and integrated review and practice activities.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison classrooms with prerecorded storybooks including target vocabulary but without explicit instruction, focusing on general language enrichment strategies.
Number of subjects: 84
Study: 35460734

Group type: EXPERIMENTAL
Intervention: Online intervention adjunct to treatment-as-usual (TAU)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 647
Study: 32005561

Group type: EXPERIMENTAL
Intervention: Repeat selective laser trabeculoplasty (SLT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Initial SLT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Repeat SLT
Number of subjects: 90
Study: 35565823

Group type: EXPERIMENTAL
Intervention: Catechin group (490 mg catechin, 0.14%, containing 59% epi-type catechin, n = 55)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo group (0 mg catechin, n = 54)
Number of subjects: 109
Study: 34837365

Group type: EXPERIMENTAL
Intervention: Behavior Change Communication (BCC) activities for mothers including interactive sessions, audio-visual film screening, and virtual hand wash demonstration.
Number of subjects: 3980

Group type: COMPARATOR
Intervention: Routine care under the National health program provided by ASHA workers (Control group).
Number of subjects: 3980
Study: 34350732

Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar pegfilgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: US-reference pegfilgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: EU-reference pegfilgrastim
Number of subjects: 0
Study: 32941526

Group type: COMPARATOR
Intervention: Bench press with traditional stable loading
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bench press with loads (2x5kg) attached as pendulums swinging forward/backwards
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bench press with loads (2x5kg) attached as pendulums swinging left/right
Number of subjects: 17

Group type: COMPARATOR
Intervention: Stable conditions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Swing in the mediolateral direction
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Swing in the anteroposterior direction
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Swinging loads (both directions)
Number of subjects: 17
Study: 35049164

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Training (HICT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Protocols
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-Intensity Protocols
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Continuous Conditions
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interval Conditions
Number of subjects: 9
Study: 34284808

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID (with initial dose titration on days 1–6)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 42
Study: 35793101

Group type: EXPERIMENTAL
Intervention: 10-mg balovaptan adult-equivalent dose
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: 4-mg balovaptan adult-equivalent dose
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Balovaptan
Number of subjects: 339
Study: 34414642

Group type: EXPERIMENTAL
Intervention: Low-power fractional CO2 laser every 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: TXA intradermal-microinjection every 2 weeks for 3 months
Number of subjects: 25
Study: 36408238

Group type: EXPERIMENTAL
Intervention: Jiaotaiwan (2-g JTW granules, b.i.d. for 7 days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (2-g placebo granules, b.i.d. for 7 days)
Number of subjects: 128
Study: 36286633

Group type: EXPERIMENTAL
Intervention: UDCA Ursofalk (Germany) at a dose of 10 mg/kg for at least 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: UDCA (another manufacturer) at a dose of 10 mg/kg for at least 6 months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: UDCA Ursofalk (Germany)
Number of subjects: 65

Group type: COMPARATOR
Intervention: UDCA (another manufacturer)
Number of subjects: 65
Study: 35771692

Group type: EXPERIMENTAL
Intervention: Intervention related to lifestyle change for prediabetes; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) and nurses' views on prediabetes management; specific intervention details not available.
Number of subjects: 0
Study: 35597718

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch applied 2–8 hours before puncture.
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment (only covering material).
Number of subjects: 92
Study: 32318963

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 170

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Low-dose DOACs (edoxaban or rivaroxaban)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Normal-dose DOACs (edoxaban or rivaroxaban)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Rivaroxaban and Warfarin (for hemopericardium)
Number of subjects: 170
Study: 34332155

Group type: EXPERIMENTAL
Intervention: Accelerated bilateral TBS at 80% resting motor threshold
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Accelerated bilateral TBS at 120% resting motor threshold
Number of subjects: 300

Group type: COMPARATOR
Intervention: Left unilateral 10 Hz rTMS
Number of subjects: 300
Study: 32138728

Group type: EXPERIMENTAL
Intervention: Duck circovirus (DuCV) infection
Number of subjects: 848
Study: 35144670

Group type: EXPERIMENTAL
Intervention: Progression criteria
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pilot trial feasibility
Number of subjects: 35
Study: 35593677

Group type: EXPERIMENTAL
Intervention: repeated remote ischemic postconditioning (rIPostC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: sham-conditioning
Number of subjects: 88
Study: 34311420

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 513
Study: 32479166

Group type: EXPERIMENTAL
Intervention: Rituximab infusion every 6 months for 18 months (4 infusions)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo infusion every 6 months for 18 months (4 infusions)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Rituximab infusion
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 97
Study: 32663852

Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin + clavulanic acid 1 hour before surgery and 1 g amoxicillin + clavulanic acid twice a day for 5 days after surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: No perioperative antibiotic therapy
Number of subjects: 75
Study: 35819441

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33143514

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 122421

Group type: COMPARATOR
Intervention: No cholecystectomy (Control)
Number of subjects: 122421
Study: 35405099

Group type: EXPERIMENTAL
Intervention: ACEI/ARB discontinuation in mild disease
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: ACEI/ARB continuation in moderate disease
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: ACEI/ARB discontinuation in moderate disease
Number of subjects: 659
Study: 34333575

Group type: EXPERIMENTAL
Intervention: Condom use as the sole form of contraception (n = 137)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Dual protection (using condoms and another form of contraception)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Condoms and the pill
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 698
Study: 32844723

Group type: EXPERIMENTAL
Intervention: RUC-4 at 0.05 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: RUC-4 at 0.075 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: RUC-4 at 0.04 mg/kg
Number of subjects: 32
Study: 35389050

Group type: EXPERIMENTAL
Intervention: Combined nomogram model incorporating deep learning predictive probability and clinical factors
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Arterial enhancement level
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Deep learning predictive probability
Number of subjects: 104
Study: 32493029

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 75
Study: 33914304

Group type: EXPERIMENTAL
Intervention: Integrated management (IM) group: offline medical and nursing management combined with WeChat online management.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group: routine nursing intervention.
Number of subjects: 140
Study: 35662314

Group type: EXPERIMENTAL
Intervention: PW‐PAD group
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 394
Study: 34785365

Group type: EXPERIMENTAL
Intervention: 10Hz M1‐rTMS over 2 weeks (real treatment)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment (sham control)
Number of subjects: 27
Study: 34050044

Group type: EXPERIMENTAL
Intervention: Robotic arm group (RG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Free-hand group (FG)
Number of subjects: 24
Study: 32615951

Group type: EXPERIMENTAL
Intervention: Crowdsourcing materials to promote HCV testing (administered once a week for two weeks)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: No promotional materials (control group)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Crowdsourcing materials to promote HCV testing
Number of subjects: 1006
Study: 34597468

Group type: EXPERIMENTAL
Intervention: Mobile phone based application (My Baby's Movements and Me)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard care (written brochure about fetal movements and clinical practice guideline)
Number of subjects: 3
Study: 33826614

Group type: EXPERIMENTAL
Intervention: Genomics-enabled arm (binimetinib)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Alternate treatment arm
Number of subjects: 27
Study: 36164048

Group type: EXPERIMENTAL
Intervention: Pola-R-CHP
Number of subjects: 879

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 879
Study: 33737414

Group type: EXPERIMENTAL
Intervention: Tap dance training (TD) for 16 weeks (60 min/session×3 sessions/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group attended four educational workshops (1 hour/session×1 session/month)
Number of subjects: 40
Study: 32000630

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 6136
Study: 36182728

Group type: EXPERIMENTAL
Intervention: Nursing Competency Evaluation system (multimedia items)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Text-based mobile test (control group)
Number of subjects: 60
Study: 34329577

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide (5 g/m2), carboplatin (AUC 5), and etoposide (100 mg/m2) for two 21-day cycles.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide, carboplatin, and etoposide.
Number of subjects: 45
Study: 33000415

Group type: EXPERIMENTAL
Intervention: Tongyan Spray (通咽喷雾剂) applied to the pharynx 30 min before examination
Number of subjects: 72

Group type: COMPARATOR
Intervention: Purified water at room temperature (placebo)
Number of subjects: 72
Study: 36065697

Group type: EXPERIMENTAL
Intervention: Modeling group (161 patients)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Validation group (69 patients)
Number of subjects: 230
Study: 33258064

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 36055230

Group type: EXPERIMENTAL
Intervention: ctDNA-guided risk-stratification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study: 34862418

Group type: EXPERIMENTAL
Intervention: 900 MHz mobile phone radiofrequency exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control parameters (not specified)
Number of subjects: 0
Study: 36373469

Group type: EXPERIMENTAL
Intervention: Automated Personalized Self-Care (APSC) program
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 35197420

Group type: EXPERIMENTAL
Intervention: Alteplase at 0.6 mg/kg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 126
Study: 33953542

Group type: EXPERIMENTAL
Intervention: 25 mg empagliflozin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5 mg lobeglitazone sulfate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of 25 mg empagliflozin and 0.5 mg lobeglitazone sulfate
Number of subjects: 30
Study: 32988385

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MTZ) 10 mg/kg for 30 days in HET mice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MTZ) for insomnia and mood disorders in RTT patients
Number of subjects: 80
Study: 35417538

Group type: EXPERIMENTAL
Intervention: BCG + Oral Polio Vaccine (OPV) immediately
Number of subjects: 1451

Group type: COMPARATOR
Intervention: BCG + Oral Polio Vaccine (OPV) at hospital discharge
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Unvaccinated neonates
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Vaccinated neonates
Number of subjects: 1451
Study: 34184474

Group type: EXPERIMENTAL
Intervention: Ampasse (5 mg/ml, 5 ml intravenously bolus slowly for 15 days)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, 5 ml)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ampasse
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 32294619

Group type: COMPARATOR
Intervention: CON (17 minutes CON only)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SELF (self-determined warm-up)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPC (IPC + CON)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PAP (CON + PAP)
Number of subjects: 12
Study: 35596578

Group type: EXPERIMENTAL
Intervention: THC (8 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: THC + CBD (8 mg THC + 10 mg CBD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CBD (600 mg, oral)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33583165

Group type: COMPARATOR
Intervention: Duloxetine alone (Group I)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Duloxetine + Okada Purifying Therapy (Group II)
Number of subjects: 31
Study: 33842006

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 70

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 70
Study: 33612615

Group type: EXPERIMENTAL
Intervention: High Protein Diet and Exercise (HPDE; n=15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High Protein Diet (HPD; n=15)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Group (CG; n=13)
Number of subjects: 43
Study: 35350919

Group type: EXPERIMENTAL
Intervention: Primary intensivists and nurses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 34165151

Group type: EXPERIMENTAL
Intervention: CVRS2 design treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CVRS approach
Number of subjects: 0
Study: 33345876

Group type: EXPERIMENTAL
Intervention: Dapagliflozin-Metformin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 66
Study: 33902611

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) and ivermectin (IVM)
Number of subjects: 864

Group type: COMPARATOR
Intervention: Control villages (not specified)
Number of subjects: 864
Study: 33067493

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wait-list control for 8 weeks
Number of subjects: 28
Study: 36104738

Group type: EXPERIMENTAL
Intervention: 2-month choice architecture intervention (menu labelling, prompts, item positioning, feedback)
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Usual online ordering
Number of subjects: 1331
Study: 33617194

Group type: EXPERIMENTAL
Intervention: Intratympanic FX‐322
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 32559044

Group type: EXPERIMENTAL
Intervention: Periodontally accelerated osteogenic orthodontics (PAOO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 35112424

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) intervention
Number of subjects: 397

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 397
Study: 34684336

Group type: EXPERIMENTAL
Intervention: Coffee + milk
Number of subjects: 14

Group type: COMPARATOR
Intervention: Milk (control)
Number of subjects: 14
Study: 33096362

Group type: EXPERIMENTAL
Intervention: Medication Safety Enhancement (MSE) simulation program with integrated technology
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard training (Control)
Number of subjects: 83
Study: 35660539

Group type: EXPERIMENTAL
Intervention: APOL1 genotyping with clinical decision support (CDS) results returned immediately
Number of subjects: 6650

Group type: COMPARATOR
Intervention: Control group receiving CDS results at 6 months
Number of subjects: 6650

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing for relevant antihypertensive medications
Number of subjects: 6650
Study: 33020052

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100 μg or 4,000 units daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35022783

Group type: EXPERIMENTAL
Intervention: suvorexant 10-20 mg nightly for 4 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: suvorexant
Number of subjects: 56
Study: 33389236

Group type: EXPERIMENTAL
Intervention: Biofloc technology (BFT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Recirculating aquaculture systems (RAS)
Number of subjects: 64